
    
      This is a prospective, single arm study. To evaluate the safety and efficacy of sequential
      CD19 and CD22 CAR-T cells in the treatment of adult newly diagnosed Ph chromosome negative
      B-cell acute lymphoblastic leukemia. The main endpoints were dose limiting toxicity (DLT) and
      incidence of adverse events (TEAEs).
    
  